Logo image of OMIC

SINGULAR GENOMICS SYSTEMS IN (OMIC) Stock Fundamental Analysis

NASDAQ:OMIC - Nasdaq - US82933R3084 - Common Stock - Currency: USD

19.93  +0.02 (+0.1%)

Fundamental Rating

2

Overall OMIC gets a fundamental rating of 2 out of 10. We evaluated OMIC against 57 industry peers in the Life Sciences Tools & Services industry. OMIC scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. OMIC is quite expensive at the moment. It does show a decent growth rate.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

OMIC had negative earnings in the past year.
OMIC had a negative operating cash flow in the past year.
OMIC had negative earnings in each of the past 5 years.
In the past 5 years OMIC always reported negative operating cash flow.
OMIC Yearly Net Income VS EBIT VS OCF VS FCFOMIC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M -100M

1.2 Ratios

OMIC's Return On Assets of -46.27% is on the low side compared to the rest of the industry. OMIC is outperformed by 87.72% of its industry peers.
OMIC's Return On Equity of -70.04% is on the low side compared to the rest of the industry. OMIC is outperformed by 73.68% of its industry peers.
Industry RankSector Rank
ROA -46.27%
ROE -70.04%
ROIC N/A
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
OMIC Yearly ROA, ROE, ROICOMIC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for OMIC so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
OMIC Yearly Profit, Operating, Gross MarginsOMIC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 -2K -4K -6K -8K -10K

More info and screens

5

2. Health

2.1 Basic Checks

OMIC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, OMIC has less shares outstanding
The debt/assets ratio for OMIC is higher compared to a year ago.
OMIC Yearly Shares OutstandingOMIC Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 20M 40M 60M
OMIC Yearly Total Debt VS Total AssetsOMIC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 100M 200M 300M

2.2 Solvency

Based on the Altman-Z score of -3.44, we must say that OMIC is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of OMIC (-3.44) is worse than 87.72% of its industry peers.
A Debt/Equity ratio of 0.04 indicates that OMIC is not too dependend on debt financing.
With a decent Debt to Equity ratio value of 0.04, OMIC is doing good in the industry, outperforming 70.18% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Altman-Z -3.44
ROIC/WACCN/A
WACC11.82%
OMIC Yearly LT Debt VS Equity VS FCFOMIC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 100M 200M 300M

2.3 Liquidity

A Current Ratio of 7.37 indicates that OMIC has no problem at all paying its short term obligations.
With an excellent Current ratio value of 7.37, OMIC belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
A Quick Ratio of 6.67 indicates that OMIC has no problem at all paying its short term obligations.
With an excellent Quick ratio value of 6.67, OMIC belongs to the best of the industry, outperforming 84.21% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 7.37
Quick Ratio 6.67
OMIC Yearly Current Assets VS Current LiabilitesOMIC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 100M 200M 300M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 8.62% over the past year.
OMIC shows a small growth in Revenue. In the last year, the Revenue has grown by 2.54%.
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
Revenue 1Y (TTM)2.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.12%

3.2 Future

Based on estimates for the next years, OMIC will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.54% on average per year.
The Revenue is expected to grow by 108.68% on average over the next years. This is a very strong growth
EPS Next Y11.81%
EPS Next 2Y8.6%
EPS Next 3Y9.54%
EPS Next 5YN/A
Revenue Next Year9.93%
Revenue Next 2Y96.89%
Revenue Next 3Y108.68%
Revenue Next 5YN/A

3.3 Evolution

OMIC Yearly Revenue VS EstimatesOMIC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 5M 10M 15M 20M
OMIC Yearly EPS VS EstimatesOMIC Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 -10 -20 -30 -40 -50

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for OMIC. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OMIC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OMIC Price Earnings VS Forward Price EarningsOMIC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OMIC Per share dataOMIC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 -20 40

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y8.6%
EPS Next 3Y9.54%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for OMIC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

SINGULAR GENOMICS SYSTEMS IN

NASDAQ:OMIC (2/11/2025, 8:00:01 PM)

19.93

+0.02 (+0.1%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)N/A N/A
Inst Owners51%
Inst Owner Change-55.47%
Ins Owners13.96%
Ins Owner Change0.09%
Market Cap50.42M
Analysts80
Price Target12.7 (-36.28%)
Short Float %2.13%
Short Ratio2.99
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)11.66%
Min EPS beat(2)5.17%
Max EPS beat(2)18.16%
EPS beat(4)4
Avg EPS beat(4)9.18%
Min EPS beat(4)4.76%
Max EPS beat(4)18.16%
EPS beat(8)8
Avg EPS beat(8)13.23%
EPS beat(12)12
Avg EPS beat(12)13.65%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)14.44%
Min Revenue beat(2)-51.75%
Max Revenue beat(2)80.64%
Revenue beat(4)3
Avg Revenue beat(4)20.95%
Min Revenue beat(4)-51.75%
Max Revenue beat(4)80.64%
Revenue beat(8)3
Avg Revenue beat(8)-8.77%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)31.4%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-2748.21%
EPS NY rev (1m)0.83%
EPS NY rev (3m)2.37%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)37.31%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-8.68%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 18.91
P/FCF N/A
P/OCF N/A
P/B 0.41
P/tB 0.41
EV/EBITDA N/A
EPS(TTM)-35.09
EYN/A
EPS(NY)-32.25
Fwd EYN/A
FCF(TTM)-31.96
FCFYN/A
OCF(TTM)-31.79
OCFYN/A
SpS1.05
BVpS48.72
TBVpS48.72
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -46.27%
ROE -70.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-30.4%
ROA(5y)-41.68%
ROE(3y)-39.09%
ROE(5y)-60.75%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.01
Health
Industry RankSector Rank
Debt/Equity 0.04
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 10.24%
Cap/Sales 15.87%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.37
Quick Ratio 6.67
Altman-Z -3.44
F-Score3
WACC11.82%
ROIC/WACCN/A
Cap/Depr(3y)235.15%
Cap/Depr(5y)229.93%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)8.62%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%27.74%
EPS Next Y11.81%
EPS Next 2Y8.6%
EPS Next 3Y9.54%
EPS Next 5YN/A
Revenue 1Y (TTM)2.54%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.12%
Revenue Next Year9.93%
Revenue Next 2Y96.89%
Revenue Next 3Y108.68%
Revenue Next 5YN/A
EBIT growth 1Y5.24%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year10.13%
EBIT Next 3Y3.57%
EBIT Next 5YN/A
FCF growth 1Y9.01%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y2.96%
OCF growth 3YN/A
OCF growth 5YN/A